- Radiofrequency ablation (RFA) is associated with better outcomes than chemotherapy or radiotherapy in nonoperable intrahepatic cholangiocarcinoma.
Why this matters
- Small, single-institution studies had suggested efficacy for RFA, but the level of evidence was low because of patient heterogeneity, small sample sizes, or poor study design.
- Analysis of patients identified from the National Cancer Database (n=505; 86 RFA, 419 chemotherapy/radiotherapy).
- Propensity score-matched analysis (84 RFA, 84 chemotherapy/radiotherapy).
- Funding: None disclosed.
- Those who underwent RFA were more likely to have Charlson‐Deyo comorbidity scores ≥1 (55.8% vs 37.0%; P=.001), have stage I disease (65.1% vs 52.0%; P=.03), and undergo treatment at an academic facility (70.9% vs 56.8%; P=.02).
- Median follow-up, 12.3 months.
- 5-year OS was higher in the RFA group (17.1% vs 6.3%; P<.001 overall as well in the propensity-matched analysis vs p>
- A bivariate analysis showed RFA was associated with improved OS (HR, 0.46; P<.001>
- Stage I: 5-year OS, 20.1% vs 3.7% (P<.001>
- Stage II: 3-year OS, 27.2% vs 12.2% (P=.18).
- Retrospective analysis.